FIELD: pharmaceutical industry, in particular agents for viral disease treatment including HIV infection (AIDS and HIV-associated diseases).
SUBSTANCE: claimed agent in form of solution for intravenous administering contains per 1 ampoule 3 % concentrate of Fullevir (fullerenopolyaminocaproic acid sodium salt)1 g and water for injection up to 1 ml. Additionally in contains 0.9 % solution of sodium chloride or 10 % solution of human albumen in amount of 100 ml per 1 ampoule.
EFFECT: decreased viral load in lymphocytes and blood serum; increased amount of CD-4 cells.
2 cl
| Title | Year | Author | Number |
|---|---|---|---|
| ANTI-VIRAL AGENT | 2006 |
|
RU2316320C1 |
| ANTIVIRAL MEDICINE | 2007 |
|
RU2333753C1 |
| HOMO- AND HETERO-POLYAMINO ACID FULLERENE C DERIVATIVES, METHOD FOR PREPARING THEM AND BASED PHARMACEUTICAL COMPOSITIONS | 2011 |
|
RU2458914C1 |
| HYDRATED N-FULLERENE-AMINO ACID DERIVATIVES, METHOD FOR PREPARING THEM AND BASED PHARMACEUTICAL COMPOSITIONS | 2011 |
|
RU2458046C1 |
| ANTIVIRAL MEDICINE | 2007 |
|
RU2333752C1 |
| ANTIVIRAL MEDICINE | 2007 |
|
RU2333751C1 |
| AGENT OF SYSTEMIC ACTION, ITS APPLICATION, PHARMACEUTICAL COMPOSITIONS, METHODS OF TREATMENT AND PREVENTION | 2007 |
|
RU2366697C2 |
| ANTIVIRAL MEDICINE | 1991 |
|
RU2038083C1 |
| ANTIVIRAL AGENT (VERSIONS) AND TREATMENT METHOD BASED ON IT | 2005 |
|
RU2331420C2 |
| ANTIVIRAL AGENT | 1991 |
|
RU2005475C1 |
